GlassScriptPhysician profile
Christie Izutsu
NPI 1295021657
$50,272.44
in general payments reported to CMS, 2019-2025
35 companies · $28K in 2025
The $28K reported for 2025 was more than what 97% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $479 · 2020: $341 · 2021: $713 · 2022: $1,104 · 2023: $3,921 · 2024: $15K · 2025: $28K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Consulting Fee: $13K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $9,600 · Food and Beverage: $8,447 · Travel and Lodging: $3,143 · Honoraria: $788 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,937.50 |
| Consulting Fee | $12,600.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $9,600.00 |
| Food and Beverage | $8,447.19 |
| Travel and Lodging | $3,142.94 |
| Honoraria | $787.50 |
| Education | $119.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $34,883.47 | 2023-2025 | Filspari |
| Calliditas Therapeutics US INC. | $3,237.28 | 2022-2025 | Tarpeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,828.78 | 2023-2025 | Jardiance |
| Amgen INC. | $1,255.69 | 2020-2025 | Tavneos, Krystexxa, Parsabiv |
| Astrazeneca Pharmaceuticals LP | $1,251.86 | 2020-2025 | Farxiga, Lokelma |
| Lilly USA, LLC | $1,017.50 | 2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $767.83 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $576.02 | 2020-2025 | Acthar |
| Aurinia Pharma U.S., INC. | $560.71 | 2021-2025 | Lupkynis |
| Ardelyx, INC. | $493.79 | 2024-2025 | Ibsrela, Xphozah 30 Mg |
| Ani Pharmaceuticals, INC. | $453.92 | 2022-2025 | Purified Cortrophin Gel |
| Vifor Pharma, INC. | $335.36 | 2019-2024 | Veltassa, Korsuva |
| Glaxosmithkline, LLC. | $333.95 | 2021-2024 | Benlysta |
| Horizon Therapeutics Plc | $329.01 | 2020-2023 | Krystexxa |
| Veloxis Pharmaceuticals, INC. | $219.92 | 2023-2025 | Envarsus |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $212.96 | 2019-2025 | Jynarque |
| Novo Nordisk INC | $185.78 | 2024-2025 | Ozempic, Rybelsus |
| Alexion Pharmaceuticals, INC. | $174.38 | 2019-2025 | Ultomiris |
| Mallinckrodt Enterprises LLC | $161.17 | 2019 | |
| Novartis Pharmaceuticals Corporation | $157.84 | 2019-2025 | |
| Amarin Pharma, INC. | $157.65 | 2020-2021 | |
| Abbvie INC. | $137.05 | 2022-2025 | |
| Vapotherm INC | $108.74 | 2019 | |
| Kyowa Kirin, INC. | $84.00 | 2023-2025 | Crysvita |
| Akebia Therapeutics INC | $81.51 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $52.98 | 2023-2024 | Oxlumo |
| Baxter Healthcare | $38.73 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.48 | 2023 | Livtencity |
| Sanofi-Aventis U.S. LLC | $24.91 | 2025 | |
| Genentech USA, INC. | $22.92 | 2025 | Gazyva |
| Allergan, INC. | $21.77 | 2019 | |
| Pfizer INC. | $21.26 | 2019 | |
| Exact Sciences Corporation | $21.05 | 2025 | The Cologuard Plus Collection Kit |
| Nxstage Medical, INC. | $14.85 | 2023 | Nxstage System One |
| Scpharmaceuticals INC. | $14.32 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christie Izutsu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.